MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conn, P. M.
Right arrow Articles by Janovick, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conn, P. M.
Right arrow Articles by Janovick, J. A.
Molecular Interventions 2:308-316 (2002)
© 2002 American Society of Pharmacology and Experimental Therapeutics


Review

Protein Origami

Therapeutic Rescue of Misfolded Gene Products

P. Michael Conn, Alfredo Leaños-Miranda and Jo Ann Janovick

Oregon National Primate Research Center and Department of Physiology and Pharmacology Oregon Health & Science University 505 NW 185th Avenue Beaverton, OR 97006

Correspondence: Address correspondence to PMC. E-mail connm{at}ohsu.edu; fax 503-690-5569.


Receptor mutations that elicit loss of function are sometimes equated with defects that ablate receptor-ligand binding or receptor-effector interactions. Similarly, mutationally defective enzymes and ion channels are often viewed as compromised in substrate or ion recognition, respectively. Recent observations, however, suggest that an alternate mechanism may be surprisingly common, namely, that mutations in structural genes may not interfere with the inherent functionality of the affected protein, but nevertheless cause disease by preventing the cell’s trafficking machinery from placing the affected protein at the appropriate subcellular compartment (e.g., at the cell membrane). Accordingly, therapies may be devised to ensure the placement of receptors (or other proteins) at locations where they can support cell function.




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick
G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo
Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J. A. Janovick, S. P. Brothers, P. E. Knollman, and P. M. Conn
Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand
FASEB J, February 1, 2007; 21(2): 384 - 392.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
S. P Brothers, J. A. Janovick, and P M. Conn
Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression
J. Mol. Endocrinol., December 1, 2006; 37(3): 479 - 488.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
P. M. Conn, P. E. Knollman, S. P. Brothers, and J. A. Janovick
Protein Folding as Posttranslational Regulation: Evolution of a Mechanism for Controlled Plasma Membrane Expression of a G Protein-Coupled Receptor
Mol. Endocrinol., December 1, 2006; 20(12): 3035 - 3041.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
P M. Conn, J. A. Janovick, S. P Brothers, and P. E Knollman
'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation.
J. Endocrinol., July 1, 2006; 190(1): 13 - 16.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. A. Janovick, P. E. Knollman, S. P. Brothers, R. Ayala-Yanez, A. S. Aziz, and P. M. Conn
Regulation of G Protein-coupled Receptor Trafficking by Inefficient Plasma Membrane Expression: MOLECULAR BASIS OF AN EVOLVED STRATEGY
J. Biol. Chem., March 31, 2006; 281(13): 8417 - 8425.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. Castro-Fernandez, G. Maya-Nunez, and P. M. Conn
Beyond the Signal Sequence: Protein Routing in Health and Disease
Endocr. Rev., June 1, 2005; 26(4): 479 - 503.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Leanos-Miranda, A. Ulloa-Aguirre, J. A. Janovick, and P. M. Conn
In Vitro Coexpression and Pharmacological Rescue of Mutant Gonadotropin-Releasing Hormone Receptors Causing Hypogonadotropic Hypogonadism in Humans Expressing Compound Heterozygous Alleles
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3001 - 3008.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. J. Pask, H. Kanasaki, U. B. Kaiser, P. M. Conn, J. A. Janovick, D. W. Stockton, D. L. Hess, M. J. Justice, and R. R. Behringer
A Novel Mouse Model of Hypogonadotrophic Hypogonadism: N-Ethyl-N-Nitrosourea-Induced Gonadotropin-Releasing Hormone Receptor Gene Mutation
Mol. Endocrinol., April 1, 2005; 19(4): 972 - 981.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. P. Brothers, A. Cornea, J. A. Janovick, and P. M. Conn
Human Loss-of-Function Gonadotropin-Releasing Hormone Receptor Mutants Retain Wild-Type Receptors in the Endoplasmic Reticulum: Molecular Basis of the Dominant-Negative Effect
Mol. Endocrinol., July 1, 2004; 18(7): 1787 - 1797.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. P. Millar, Z.-L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley
Gonadotropin-Releasing Hormone Receptors
Endocr. Rev., April 1, 2004; 25(2): 235 - 275.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. P. Brothers, J. A. Janovick, and P. M. Conn
Unexpected Effects of Epitope and Chimeric Tags on Gonadotropin-Releasing Hormone Receptors: Implications for Understanding the Molecular Etiology of Hypogonadotropic Hypogonadism
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6107 - 6112.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Leanos-Miranda, A. Ulloa-Aguirre, T. H. Ji, J. A. Janovick, and P. M. Conn
Dominant-Negative Action of Disease-Causing Gonadotropin-Releasing Hormone Receptor (GnRHR) Mutants: A Trait That Potentially Coevolved with Decreased Plasma Membrane Expression of GnRHR in Humans
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3360 - 3367.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. A. Janovick, M. Goulet, E. Bush, J. Greer, D. G. Wettlaufer, and P. M. Conn
Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 608 - 614.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.